STAIR Stable Method™: A Pre-Stabilization Protocol for Hypersensitive Patients

By Cynthia Adinig, Founder of CYNAERA

For those of us with MCAS, ME/CFS, Long COVID, POTS, or MCS, even 1/4th of a pill can mean an ER trip. I’ve lived it. I built STAIR Stable Method™ — Stabilization, Tolerance, And Immune Readiness, to change that. First introduced in CYNAERA’s latest white paper: The Science of Remission: Reversing the Terrain of Infection-Associated Chronic Conditions (IACCs), STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”

Why I Built STAIR Stable Method™

This protocol wasn’t drafted in theory. I built it while trying to survive a body that reacted to nearly everything. I’ve had dangerous reactions to things most clinicians consider safe, quercetin, vitamin C, even a prescribed beta blocker. I once had an allergic type reaction just from touching tap water during a severe flare. I know what it means to live at that level of reactivity.

That experience is part of why I was brought in to advise the Mt. Sinai team under Dr. David Putrino, as they worked to support patients across ME/CFS, Long COVID, Lyme, and MS. I helped them improve their clinic process for identifying high-risk patients, guided provider education strategies, and contributed to developing new CME focused on managing complex, hypersensitive cases.

STAIR builds on that work, but goes deeper. It includes tools and timing strategies that didn’t exist in the clinic setting, things I had to develop from a variety of patient community insights and myself when no roadmap fit the reality of my body. What emerged is a system that bridges lived experience and clinical logic, offering a way forward when most protocols stop working.

What STAIR Stable Method™ Is

STAIR is not a treatment. It’s a biological preparation protocol to reduce risk and support tolerability before engaging with any new intervention. It’s modular, scalable, and grounded in the systems most often destabilized in IACC patients: immune, autonomic, and hormonal.

It’s particularly useful for:

• Clinical trial ramp-up windows

• First exposures to new therapeutics

• Patients previously rejected from studies due to instability

• Those who have “tried everything” and still react to everything

STAIR Interventions (9–14 Days Prep Window)

We categorize recommended supports into three tiers based on sensitivity level and exposure risk.

🔹 Core Stabilizers (Most Patients)

Function	Recommendation
H1 Blockade	Cetirizine 10 mg or Loratadine 10 mg daily
H2 Blockade	Famotidine 20–40 mg once or twice daily
Mast Cell Stabilizer	Cromolyn sodium (GI) or Ketotifen (start ≥4 weeks early)
Buffered Vitamin C	Sodium ascorbate or Ester-C
Hydration	Clean electrolytes or ORS
Nutrition	Low-histamine, MCAS-safe meals only

🟡 Optional Add-Ons (Moderate Sensitivity)

Function	Recommendation
Immune Modulation	Montelukast 10 mg (if tolerated)
Flavonoids	Quercetin 250–500 mg, Luteolin (optional)
Antioxidants	NAC or glutathione precursors
Probiotics	Only low-histamine strains (e.g., B. infantis)

🔴 High-Risk Modifiers (Provider Oversight Required)

Function	Recommendation
Corticosteroid Buffer	Prednisone 5–10 mg (Rx only)
Emergency Safety	Diphenhydramine, EpiPen, rescue inhaler on hand
Autonomic Support	Midodrine or fludrocortisone (if prescribed)
Symptom Suppression	Acetaminophen (for post-exposure immune spikes)

Day of Trial

• Repeat H1/H2 antihistamines

• Take prescribed mast cell stabilizers or steroids

• Hydrate + rest in a calm, fragrance-free space

• Avoid stimulation for 4–8 hours post-exposure

• Track symptoms for 48 hours

Why It Works

Most adverse reactions don’t happen because a substance is “too strong.” They happen because the terrain is too unstable. STAIR cushions the body’s stress systems and immune thresholds, especially in patients with known cycle flares, trauma-linked hypersensitivity, or immune rebound patterns. We’ve seen this method:

• Prevent hormone-linked cycle crashes

• Increase tolerability to medications after years of failed attempts

• Help patients avoid ER-level escalation by preparing their body before exposure

STAIR Stable Method™ Is Just the Beginning

The full power of this model comes when it’s personalized. The most severe patients can and should take a more measured approach that could last weeks to months.

We’ll soon be offering a small opportunity to receive individualized stabilization maps powered by CYNAERA’s AI-driven modules and medicine engine, tuned for patients who’ve been sick the longest, tried the most, and been written off by traditional care systems.

No cost, no pressure, no miracle claims. Just a system built for people who were left out of every other one.

Get Early Access to Personalized Stabilization

Author’s Note:

All insights, frameworks, and recommendations in this white paper reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Applied Infrastructure Models Supporting This Analysis

Several standardized diagnostic and forecasting models developed through CYNAERA were utilized or referenced in the construction of this white paper. These tools support real-time surveillance, economic forecasting, and symptom stabilization planning for infection-associated chronic conditions (IACCs).

Note: These models were developed to bridge critical infrastructure gaps in early diagnosis, stabilization tracking, and economic impact modeling. Select academic and public health partnerships may access these modules under non-commercial terms to accelerate independent research and system modernization efforts.

Licensing and Customization

Enterprise, institutional, and EHR/API integrations are available through CYNAERA Market for organizations seeking to license, customize, or scale CYNAERA's predictive systems.

Learn More: https://www.cynaera.com/systems

About the Author 

Cynthia Adinig is an internationally recognized systems strategist, health policy advisor, and the founder of CYNAERA, an AI-powered intelligence platform advancing diagnostic reform, clinical trial simulation, and real-world modeling for infection-associated chronic conditions (IACCs). She has developed 400+ Core AI Frameworks, 1 Billion + Dynamic AI Modules. including the IACC Progression Continuum™, US-CCUC™, and RAEMI™, which reveal hidden prevalence, map disease pathways, and close gaps in access to early diagnosis and treatment.

Her clinical trial simulator, powered by over 675 million synthesized individual profiles, offers unmatched modeling of intervention outcomes for researchers and clinicians.

Cynthia has served as a trusted advisor to the U.S. Department of Health and Human Services, collaborated with experts at Yale and Mount Sinai, and influenced multiple pieces of federal legislation related to Long COVID and chronic illness. 

She has been featured in TIME, Bloomberg, USA Today, and other leading publications. Through CYNAERA, she develops modular AI platforms that operate across 32+ sectors and 180+ countries, with a local commitment to resilience in the Northern Virginia and Washington, D.C. region.